<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099589</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2121</org_study_id>
    <nct_id>NCT04099589</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma</brief_title>
  <official_title>Multicenter Phase II Study of Gemcitabine/Cisplatin (GC) Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) in the Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder&#xD;
      cancer, especially chemotherapy combined with immunotherapy, however, available data of&#xD;
      retrospective studies showed this neoadjuvant treatment model might benefit patients. So This&#xD;
      prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy&#xD;
      combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive&#xD;
      bladder urothelial carcinoma, then to improve the rate of complete pathological remission,&#xD;
      survival and provide medical evidence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>through study completion of 3 years</time_frame>
    <description>the percentage of pT0N0 patients after operations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Upper Tract Urinary Carcinoma</condition>
  <condition>Muscle-invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MIBC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UTUC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Gemcitabine/Cisplatin plus Toripalimab</description>
    <arm_group_label>MIBC Group</arm_group_label>
    <arm_group_label>UTUC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. bladder cancer of T2-4aN0M0&#xD;
&#xD;
          2. upper tract urinary carcinoma of T1-3N0M0 and high grade&#xD;
&#xD;
          3. ECOG 0-1&#xD;
&#xD;
          4. good organ function&#xD;
&#xD;
          5. no previous chemotherapy or immunotherapy&#xD;
&#xD;
          6. Informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. unable to receive chemotherapy or surgery due to physical abnormalities&#xD;
&#xD;
          2. previous cancer history&#xD;
&#xD;
          3. active tuberculosis&#xD;
&#xD;
          4. HIV&#xD;
&#xD;
          5. autoimmune disease&#xD;
&#xD;
          6. anticipating other clinical studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianzhong Shou</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianzhong Shou</last_name>
    <phone>86-18813019104</phone>
    <email>chuanzhenc@yeah.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Shou, MD</last_name>
      <phone>13601332989</phone>
      <email>shoujzh@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianzhong Shou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>upper tract urinary carcinoma</keyword>
  <keyword>muscle-invasive bladder cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

